709 filings
Page 4 of 36
8-K
d4gqwswal4cl8ijh53s
12 Nov 21
Viveve Reports Third Quarter 2021 Financial Results and Provides Corporate Update
8:29am
8-K
eksggzzuzec8gwgbd
28 Oct 21
Issuance further expands and strengthens Company’s intellectual property portfolio
8:29am
8-K
gu6cd9g t5
23 Sep 21
Viveve Announces Issuance of New Method Patent for Stress Urinary Incontinence in Australia
8:29am
8-K
7gctburmkig5 4bqg
7 Sep 21
Viveve to Participate in H.C. Wainwright 23rd Annual Global Investment Conference
8:29am
8-K
4hw480mnsew3l03
12 Aug 21
Viveve Reports Second Quarter 2021 Financial Results and Provides Corporate Update
4:02pm
8-K
dsxir3f3wrrp77xg
3 Aug 21
Viveve Announces Continued Expansion of IP Portfolio with Issuance of Canadian Patent
8:29am
UPLOAD
xlqnkh1
12 Jul 21
Letter from SEC
12:00am
8-K
132 muyxu9oznj
7 Jul 21
Viveve Announces New Category III CPT Code for its Stress Urinary Incontinence Procedure
8:29am
8-K
xhod li3o
6 Jul 21
Viveve to Participate in Ladenburg Thalmann Healthcare Virtual Conference
8:29am
S-8
e6pvueb 73n
2 Jul 21
Registration of securities for employees
4:19pm
8-K
ppgfrn2asvvrum727m9g
25 Jun 21
Departure of Directors or Certain Officers
4:02pm
DEFA14A
jllxno2
16 Jun 21
Additional proxy soliciting materials
7:03am
8-K
mgb3xd zb9qj5
16 Jun 21
Amendments to Articles of Incorporation or Bylaws
7:01am
8-K
g2qbwl0u34qtln9mh3
10 Jun 21
Issuance expands patent claims for Company’s dual-energy technology
8:29am
8-K
6jvir7r9gnz3
2 Jun 21
Viveve Announces Adjournment of Annual Meeting
4:10pm
DEFA14A
lbib2yk5u02oa oq
2 Jun 21
Additional proxy soliciting materials
4:08pm